Sara Lucas Del Pozo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Lucas Del Pozo has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Henry Vernon Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
7 shared publications - Sofia Koletsi
Anthony schapira UCL University College London University of London
5 shared publications - David Moreno-Martínez
Lysosomal Storage Disorders Unit Royal Free Hospital NHS Foundation Trust and University College London London UK
4 shared publications - Elisa Menozzi
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
4 shared publications - Jorge Hernández-Vara
Hospital Universitario Vall d’Hebron, 08035 Barcelona, Spain
4 shared publications - Marco Toffoli
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
4 shared publications
Latest Publications
- Open Access
- 7 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70415
Stroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single‐Centre Cohort
Objectives: Risk factors for stroke in Fabry disease (FD) are not precisely known. This study presents a retrospective cohort analysis from one reference centre in the United Kingdom to determine risk factors for stroke and to develop a predictive model. Methods: Patients > 18 years old were included in the study and were followed from their first visit until March 2019. The main outcome of the survival analysis was time to stroke. The independent risk factors were evaluated using a multivariate Cox regression. Results: Of 414 patients, 368 were included in the survival analysis. 227 (61.7%) were female, with a median baseline age of 42.7 (IQR 27.8–54.8) for males and 39.9 (26.6–51.2) years for females. 56 (39.7%) males and 64 (28.2%) females had the N215S genotype. 41 patients had a stroke at baseline (11.2%), rising to 69 (18.8%) at the end—66.7% lacunar, 18.9% anterior circulation, 13% posterior circulation and 1.4% venous thrombosis. Median follow‐up was 10.4 years. Median time to stroke in males and females was 43 (43–43) and 58 (58–59) years, respectively. In the multivariate analysis, a concomitant autoimmune disease was associated with an increased risk of stroke, while glomerular filtration rate > 90 and N215S genotype were associated with a decreased risk. Interpretation: Sex was not associated with stroke, despite males being more severe. These results might help stratify patients and are of interest not only to metabolic physicians, but to general stroke physicians too.
- 7 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70415
Open AccessStroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single‐Centre Cohort
Objectives: Risk factors for stroke in Fabry disease (FD) are not precisely known. This study presents a retrospective cohort analysis from one reference centre in the United Kingdom to determine risk factors for stroke and to develop a predictive model. Methods: Patients > 18 years old were included in the study and were followed from their first visit until March 2019. The main outcome of the survival analysis was time to stroke. The independent risk factors were evaluated using a multivariate Cox regression. Results: Of 414 patients, 368 were included in the survival analysis. 227 (61.7%) were female, with a median baseline age of 42.7 (IQR 27.8–54.8) for males and 39.9 (26.6–51.2) years for females. 56 (39.7%) males and 64 (28.2%) females had the N215S genotype. 41 patients had a stroke at baseline (11.2%), rising to 69 (18.8%) at the end—66.7% lacunar, 18.9% anterior circulation, 13% posterior circulation and 1.4% venous thrombosis. Median follow‐up was 10.4 years. Median time to stroke in males and females was 43 (43–43) and 58 (58–59) years, respectively. In the multivariate analysis, a concomitant autoimmune disease was associated with an increased risk of stroke, while glomerular filtration rate > 90 and N215S genotype were associated with a decreased risk. Interpretation: Sex was not associated with stroke, despite males being more severe. These results might help stratify patients and are of interest not only to metabolic physicians, but to general stroke physicians too.
- Open Access
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Open AccessSevere GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- Open Access
Microbiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.
Open AccessMicrobiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.
- Open Access
Simulated microgravity accelerates alpha-synuclein aggregation and induces oxidative stress in an in vitro Parkinson’s disease model
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the accumulation of alpha-synuclein aggregates and progressive neuronal loss in the substantia nigra, with aging being its primary risk factor. The current available models to study PD mechanisms are largely relying on genetic mutations to recapitulate PD typical hallmarks, such as increased alpha-synuclein aggregation. However, they do not model the aging features associated with the disease. Microgravity, a condition experience by astronauts during space missions, is known to induce ageing-like modifications on both systemic and cellular physiology. To replicate the aging-related stress observed in PD patients, we exposed SH-SY5Y and 3K-SNCA mutant cell lines to simulated microgravity. Our findings revealed that simulated microgravity enhanced PD alterations, with a significant increase in misfolded and phosphorylated a-syn. This was accompanied by heightened oxidative stress, as evidenced by increased levels of reactive oxygen species, without a sufficient antioxidant response. These results suggest that simulated microgravity effectively mimics and accelerate the stress associated with aging in PD cell models, regardless of the presence of PD mutation. This study highlights the potential of simulated microgravity as a tool for investigating aging processes in neurodegenerative diseases.
Open AccessSimulated microgravity accelerates alpha-synuclein aggregation and induces oxidative stress in an in vitro Parkinson’s disease model
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the accumulation of alpha-synuclein aggregates and progressive neuronal loss in the substantia nigra, with aging being its primary risk factor. The current available models to study PD mechanisms are largely relying on genetic mutations to recapitulate PD typical hallmarks, such as increased alpha-synuclein aggregation. However, they do not model the aging features associated with the disease. Microgravity, a condition experience by astronauts during space missions, is known to induce ageing-like modifications on both systemic and cellular physiology. To replicate the aging-related stress observed in PD patients, we exposed SH-SY5Y and 3K-SNCA mutant cell lines to simulated microgravity. Our findings revealed that simulated microgravity enhanced PD alterations, with a significant increase in misfolded and phosphorylated a-syn. This was accompanied by heightened oxidative stress, as evidenced by increased levels of reactive oxygen species, without a sufficient antioxidant response. These results suggest that simulated microgravity effectively mimics and accelerate the stress associated with aging in PD cell models, regardless of the presence of PD mutation. This study highlights the potential of simulated microgravity as a tool for investigating aging processes in neurodegenerative diseases.
- Open Access
- 11 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (12) , 2144-2154
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Glucocerebrosidase (GBA1) variants constitute numerically the most common known genetic risk factor for Parkinson's disease (PD) and are distributed worldwide. Access to GBA1 genotyping varies across the world and even regionally within countries. Guidelines for GBA1 variant counseling are evolving. We review the current knowledge of the link between GBA1 and PD, and discuss the practicalities of GBA1 testing. Lastly, we provide a consensus for an approach to counseling people with GBA1 variants, notably the communication of PD risk. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 11 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (12) , 2144-2154
Open AccessConsensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Glucocerebrosidase (GBA1) variants constitute numerically the most common known genetic risk factor for Parkinson's disease (PD) and are distributed worldwide. Access to GBA1 genotyping varies across the world and even regionally within countries. Guidelines for GBA1 variant counseling are evolving. We review the current knowledge of the link between GBA1 and PD, and discuss the practicalities of GBA1 testing. Lastly, we provide a consensus for an approach to counseling people with GBA1 variants, notably the communication of PD risk. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model
Parkinson disease is a neurodegenerative disorder characterised by impairment of motor function, and is associated with a progressive accumulation of insoluble aggregates of misfolded alpha-synuclein. In the present study, we exploited the SH-SY5Y cell model overexpressing a pro-aggregation form of alpha-synuclein to investigate the efficacy of PIKfyve-mediated lysosomal biogenesis, through TFEB, as potential target for Parkinson therapy. To investigate this, we exploited high-content imaging along with enzymatic assays to follow the progression of lysosomal biogenesis, lysosomal function and alpha-synuclein accumulation. The cellular model exploited in this study recapitulated important elements of the biochemical phenotype observed in Parkinson patient-derived neurons, including synuclein aggregates and impaired glucocerebrosidase (GCase) function. PIKfyve inhibition by YM201636 resulted in a lysosomal-dependant reduction of alpha-synuclein aggregates as early as 24 hours post-treatment. The mechanism of action of YM201636 was shown to be TFEB-mediated, with an increase in TFEB in the nuclei which subsequently resulted in increased lysosomal markers LAMP1 and GCase. PIKfyve inhibtion efficacy was also tested in differentiated SH-SY5Y cells, exhibiting a neuron-like morphology. In these cells, YM201636 also significantly reduced alpha-synuclein aggregates and increased TFEB nuclear presence. These findings suggest that PIKfyve inhibition could be exploited as therapeutic target for Parkinson disease.
Open AccessReduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model
Parkinson disease is a neurodegenerative disorder characterised by impairment of motor function, and is associated with a progressive accumulation of insoluble aggregates of misfolded alpha-synuclein. In the present study, we exploited the SH-SY5Y cell model overexpressing a pro-aggregation form of alpha-synuclein to investigate the efficacy of PIKfyve-mediated lysosomal biogenesis, through TFEB, as potential target for Parkinson therapy. To investigate this, we exploited high-content imaging along with enzymatic assays to follow the progression of lysosomal biogenesis, lysosomal function and alpha-synuclein accumulation. The cellular model exploited in this study recapitulated important elements of the biochemical phenotype observed in Parkinson patient-derived neurons, including synuclein aggregates and impaired glucocerebrosidase (GCase) function. PIKfyve inhibition by YM201636 resulted in a lysosomal-dependant reduction of alpha-synuclein aggregates as early as 24 hours post-treatment. The mechanism of action of YM201636 was shown to be TFEB-mediated, with an increase in TFEB in the nuclei which subsequently resulted in increased lysosomal markers LAMP1 and GCase. PIKfyve inhibtion efficacy was also tested in differentiated SH-SY5Y cells, exhibiting a neuron-like morphology. In these cells, YM201636 also significantly reduced alpha-synuclein aggregates and increased TFEB nuclear presence. These findings suggest that PIKfyve inhibition could be exploited as therapeutic target for Parkinson disease.
- Open Access
- 23 August 2023
- Published by Springer Nature in Research Square
Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics
The importance of oral microbiota has been recently highlighted in human health, such as in Parkinson disease, notably using shotgun metagenomics. One key aspect for efficient shotgun metagenomic analysis relies on optimal microbial sampling and DNA extraction, generally implementing commercial solutions developed to improve sample collection and preservation and provide high DNA quality and quantity for downstream analysis. Because metagenomic studies are today performed on a large number of samples, the next evolution to increase study throughput is with DNA extraction automation. In this study, we proposed a semi-automated DNA extraction protocol for human salivary samples collected with a commercial kit, and compared the outcomes with the DNA extraction recommended by the manufacturer. While similar DNA yields were observed between the protocols, our semi-automated DNA protocol significantly generated higher DNA fragment sizes. Moreover, we showed that the oral microbiome composition was equivalent between DNA extraction methods, even at the species level. This study demonstrates that our semi-automated protocol is suitable for shotgun metagenomic analysis, while allowing for a better sample treatment logistic with reduced technical variability and without compromising the structure of the oral microbiome.
- 23 August 2023
- Published by Springer Nature in Research Square
Open AccessEvaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics
The importance of oral microbiota has been recently highlighted in human health, such as in Parkinson disease, notably using shotgun metagenomics. One key aspect for efficient shotgun metagenomic analysis relies on optimal microbial sampling and DNA extraction, generally implementing commercial solutions developed to improve sample collection and preservation and provide high DNA quality and quantity for downstream analysis. Because metagenomic studies are today performed on a large number of samples, the next evolution to increase study throughput is with DNA extraction automation. In this study, we proposed a semi-automated DNA extraction protocol for human salivary samples collected with a commercial kit, and compared the outcomes with the DNA extraction recommended by the manufacturer. While similar DNA yields were observed between the protocols, our semi-automated DNA protocol significantly generated higher DNA fragment sizes. Moreover, we showed that the oral microbiome composition was equivalent between DNA extraction methods, even at the species level. This study demonstrates that our semi-automated protocol is suitable for shotgun metagenomic analysis, while allowing for a better sample treatment logistic with reduced technical variability and without compromising the structure of the oral microbiome.
- Open Access
Phenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.
Open AccessPhenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.
- Open Access
Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease
Microglia are heterogenous cells characterized by distinct populations each contributing to specific biological processes in the nervous system, including neuroprotection. To elucidate the impact of sex-specific microglia heterogenicity to the susceptibility of neuronal stress, we analysed the dynamic changes in shape and motility occurring in primary mouse microglia following pro-inflammatory or neurotoxic insults, thus finding sex-specific responses of microglial subpopulations. Male microglia exhibited a pro-inflammatory phenotype, whereas female microglia showed enhanced neuroprotective capabilities associated with the activation of Nrf2 detoxification pathway in neurons. The sex difference in neuroprotective functions is lost by inhibition of glucocerebrosidase, the product of the GBA1 gene, mutations of which are the major risk factor for Parkinson’s disease (PD). This finding is consistent with the increased risk of PD observed in female carriers of GBA1 mutation, when compared with wild type population, suggesting a role for microglial functionality in the etiopathogenesis of PD-GBA1.
Open AccessSex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease
Microglia are heterogenous cells characterized by distinct populations each contributing to specific biological processes in the nervous system, including neuroprotection. To elucidate the impact of sex-specific microglia heterogenicity to the susceptibility of neuronal stress, we analysed the dynamic changes in shape and motility occurring in primary mouse microglia following pro-inflammatory or neurotoxic insults, thus finding sex-specific responses of microglial subpopulations. Male microglia exhibited a pro-inflammatory phenotype, whereas female microglia showed enhanced neuroprotective capabilities associated with the activation of Nrf2 detoxification pathway in neurons. The sex difference in neuroprotective functions is lost by inhibition of glucocerebrosidase, the product of the GBA1 gene, mutations of which are the major risk factor for Parkinson’s disease (PD). This finding is consistent with the increased risk of PD observed in female carriers of GBA1 mutation, when compared with wild type population, suggesting a role for microglial functionality in the etiopathogenesis of PD-GBA1.
- 1 January 2022
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 41 (1) , 52-54
Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers
- 1 January 2022
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 41 (1) , 52-54
Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers